Add-on Acquisition • Life Science

UTime Acquires Bowen Therapeutics

On August 28, 2024, UTime acquired life science company Bowen Therapeutics

Acquisition Context
  • This is UTime’s 1st transaction in the Life Science sector.
  • This is UTime’s 1st transaction in the United States.
  • This is UTime’s 1st transaction in Massachusetts.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free


M&A Deal Summary

Date August 28, 2024
Target Bowen Therapeutics
Sector Life Science
Buyer(s) UTime
Deal Type Add-on Acquisition

Target Company

Bowen Therapeutics

Worcester, Massachusetts, United States
Bowen Therapeutics is dedicated to the R&D of vaccines for infectious diseases. Its laboratory has previously published several research papers on the monkeypox virus and has proposed a variety of potential vaccine designs.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

UTime

Shenzhen, China

Category Company
Founded 2008
Sector Electronics
Employees99
Revenue 251M CNY (2025)
DESCRIPTION

UTime provides mobile devices to consumers globally and helps low-income individuals from established markets, including the United States, and emerging markets, such as India and countries in South Asia and Africa, have better access to updated mobile technology. The company currently transforms health and wellness through innovative medical wearable technologies. UTime was formed in 2008 and is based in Shenzhen, China.


Deal Context for Buyer #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Add-on Acquisition 1 of 1
State: Massachusetts 1 of 1
Country: United States 1 of 1
Year: 2024 1 of 1